Takeda Pharmaceutical Company Limited

Dyax Corporation

Astellas US LLC

Burt Adelman

Daniel J Sexton

Andrew Nixon

Jon A Kenniston

Ryan Faucette

Christopher TenHoor

Gregory P Conley

Stephen R Comeau

Yung Chyung

Shauna Mason

Kristopher Kopacz

Allison P Lindberg

Ryan Iarrobino

Joseph Biedenkapp

Niksa Kastrapeli

Akshay Vaishnaw

Jennifer Schranz

Christopher Tenhoor

Greg Conley

Methods and assays for determining the activation level of the plasma kallikrein (pKal) system and the uses thereof for assessing the activity of pKal modulators on the pKal system.

Assays for determining plasma kallikrein system biomarkers

Disclosed herein are anti-Factor XIIa antibodies and methods of using such for treating diseases associated with Factor XII, including diseases associated with contact system activation, plasma prekallikrein signaling (e.g., hereditary angioedema), and ocular diseases.

Monoclonal antibody inhibitor of Factor XIIa

Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.

Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

Described herein are bispecific antibodies that bind to plasma kallikrein (pKal) and Factor XII and methods of producing and using such bi-specific antibodies for treating diseases or disorders associated with the contact system, e.g., hereditary angioedema or thrombosis.

Bispecific antibodies against plasma kallikrein and factor XII

Methods, kits and compositions for diagnosing and treating autoimmune diseases such as rheumatiodi arthritis. Crohn's disease, and ulcerative colitis.

Diagnosis and treatment of autoimmune diseases

Bispecific antibodies against plasma kallikrein and Factor XII

Provided herein are plasma kallikrein antibodies binding to active plasma kallikrein and methods of using such antibodies in treating and preventing hereditary angioedema attack, such method may involve a first treatment period and optionally, a second treatment period. Also provided are methods of using such antibodies in treating hereditary angioedema involving a single dose of the antibody to a subject who has undergone a prior HAE treatment, followed by multiple doses of the same antibody if the subject experiences an HAE attack after the single dose.

Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack

The present disclosure provides methods of evaluating a subject, e.g., a subject at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder, based on values (e.g., percentages) of intact and/or cleaved kininogen in a sample of the subject. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment. Such methods can involve the use of a detection agent that preferentially binds cleaved kininogen or intact kininogen.

Methods of determining levels of cleaved and/or intact kininogen

Monoclonal antibody inhibitor of factor XIIA

Methods, kits and compositions for diagnosing and treating autoimmue diseases such as rheumatiodi arthritis, Crohn's disease, and ulcerative colitis.

Methods, kits and compositions for diagnosing and treating autoimmune diseases such as rheumatiodi arthritis, Crohn's disease, and ulcerative colitis.

Methods of treating viral disorders are disclosed.

Growing community of inventors

Concord, MA, United States of America

Burt Adelman